Experiência em 12 casos de melanoma com anticorpos monoclonais
DOI:
https://doi.org/10.32635/2176-9745.RBC.1993v39n1.2993Keywords:
Melanoma, Monoclonal Antibodies, Staging, Follow-UpAbstract
The authors present the results of scintigraphyc study in 12patients with melanoma. The twelve patients, eight males, nine white and three black, with a median age of 51.5 years old, with melanoma in varioussites, weredividedin twogroups: Grupo 1 - five cases, for disease staging; Group II – seven cases, for disease follow-up. The scintigraphyc study was realized 2, 6, 10 and 24 hours after endovenous injection of 50mCi (185OMBq) labelling monoclonal antibodies anti-melanoma (Tecnemab from Sorin). The studies were use full in detecting lesions: skin (5x); Iymphnodes (4x). Ocular, brain and soft tissues one time each independent of the scintigraphy objective (if staging or follow-up). Conclusions: 1 – little differences in concentra tion must be take in mmd; 2- the whole body study is necessary; 3- the routine must use a precocious (2-4 hours) anda tardious study (12-24 h); 4- lung metastasis are not detected often.
Downloads
References
DeL.AND F. A perspective of monoclonal antibodies: past, presente and future. Sem Nuci Med 1989; 19(3): 158-165. DOI: https://doi.org/10.1016/S0001-2998(89)80011-X
KOHLER G, MILSTEIN C. Continuous cubures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495-497. DOI: https://doi.org/10.1038/256495a0
ZUCKIERLS, RODRIGuEZLD, SCHARFFMD. lmmunologic and pharmacologic concepts of monoclonal antibodies. Sem Nuci Med 1989; 19(3): 166-186. DOI: https://doi.org/10.1016/S0001-2998(89)80012-1
BHARGANA KK, ACHARYA SA. Labeling of monoclonal anti-bodies with radionuclides. Sem Nuci Med 1989; 19(3): 187-201. DOI: https://doi.org/10.1016/S0001-2998(89)80013-3
BOGARD WC, DEAM RT, DEC, Y et al. Practical considerations in the production, purification, and formulation of monoclonal antibodies for immunoscintigraphy and immunotherapy. Sem Nuci
Med 1989; 19(3): 202-220.
Ministério da Saúde. TNM; Classificação de tumores malignos. 4a ed., Brasília; Centro de Documentação do Ministério da Saúde, 1989: 89.
SICCARDI AG, BUIRAGGI GL, CALEGARO L et al. Multicenter study of immunoscintigraphy with radiolabeled monoclonal anti-bodies in patients with melanoma. Cancer Res 1986; 46:4817-48.
BURAGGI GL, TURILLO A, CASCINELI N et al. Radioimuno-detection: preliminary results of a prospective study. Int J Biol Markers 1986; 1:47-54. DOI: https://doi.org/10.1177/172460088600100108
BOMANJI J, NIMMOM CC, HUNGERFORD JL et al. Ocular radloimmunoscintigraphy: sensitivity and practical considerations. J Nuci Med 1988; 29:1031-1037.
EARYJF, SCHROFF RW, ABRAMS PG etal. Sucessfull imaging of malignant melanomawith technetium-99m-labeled monoclonal antibodies. J Nucl Med 1989; 30: 25-32.
KEENAN AM. lmmunolymphoscintigraphy. Sem Nuci Med 1989; 19(4): 322-331. DOI: https://doi.org/10.1016/S0001-2998(89)80024-8
BOMANJI J, HuNGERFORD JL et ai. Radioimmunoscintigraphy (RIS) of eye melanomas and their metastases. In: "Nuklear Medizin: Newtrends and possibilities in Nuclear Medicine, H.A.E. Schimidt, L. Csernay eds. Shattauer Verlag, 1988: 582-589.
RIVA P, PAGANELLI G et ai. Radioimmunoscintigraphy of tumor lesions by monoclonal antibodies anti-human associated antigens. Xl Congreso Nacional de Medicina Nuclear, Santander (Espanha) 1985: 71-82.
BURAGHIGL. Tumourradioimmunodetectjon byanti-melanoma and anti-CEA monoclonal antibodies: pilot and prospective studies. In: lRadiolabeled monoclonal antibodies for imaging and therapy, Srivastana ed., Plenum Publishing Corp., New York, 1988. DOI: https://doi.org/10.1007/978-1-4684-5538-0_41
